MDCalc

Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

Measures treatment response, specifically to cytotoxic drugs, based on tumor shrinkage.

Use in liver lesions meeting the following criteria:

  • Can be accurately measured in at least one dimension as 10 mm or more (measure longest diameter).
  • Suitable for repeat measurement.
  • Intratumoral arterial enhancement on contrast-enhanced CT or MRI.
mm
mm

Diagnostic Result

Please fill out required fields.
Advice
  • Contrast-enhanced CT or MRI is the imaging modality of choice for evaluating lesions.
  • European Association for the Study of the Liver (EASL) guidelines recommend evaluating for mRECIST criteria 1 month after undergoing treatment (surgery, locoregional therapy or initiation of systemic chemotherapy).
Management

CR, complete response. PR, partial response. SD, stable disease. PD, progressive disease. IR, incomplete response.